

CADTH Reference List

Osmotic-Controlled Release Methylphenidate for the Treatment of Attention-Deficit/ Hyperactivity Disorder

September 2022

Authors: Lindsay Ritchie, Aleksandra Grobelna

Cite As: *Osmotic-Controlled Release Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder*. (CADTH reference list: summary of abstracts). Ottawa: CADTH; 2022 Sep.

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up to date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Questions or requests for information about this report can be directed to requests@cadth.ca

Key Message

We found 1 randomized controlled trial about the clinical effectiveness of extended-release methylphenidate with an osmotic-controlled release oral delivery system for the treatment of attention-deficit/hyperactivity disorder in adults.

Research Question

What is the clinical effectiveness of extended-release methylphenidate with an osmotic-controlled release oral delivery system for the treatment of attention-deficit/hyperactivity disorder in adults?

Methods

Literature Search Methods

A limited literature search was conducted by an information specialist on key resources including MEDLINE, Embase, the Cochrane Database of Systematic Reviews, the International HTA Database, and the websites of Canadian and major international health technology agencies, as well as a focused internet search. The search strategy comprised both controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. The main search concepts were methylphenidate, osmotic-controlled release oral delivery system (OROS) and attention deficit hyperactivity disorder (ADHD). No filters were applied to limit the retrieval by study type. Where possible, retrieval was limited to the human population. Comments, newspaper articles, editorials, letters, and conference abstracts were excluded. The search was completed on August 15, 2022, and limited to English-language documents published since January 1, 2012. Internet links were provided, where available.

Selection Criteria and Summary Methods

One reviewer screened literature search results (titles and abstracts) and selected publications according to the inclusion criteria presented in [Table 1](#). Full texts of study publications were not reviewed. The Overall Summary of Findings was based on information available in the abstracts of selected publications.

Results

One randomized controlled trial was identified about the clinical effectiveness of extended-release methylphenidate with an OROS for the treatment of attention-deficit/hyperactivity disorder in adults.¹ No relevant health technology assessments, systematic reviews, or non-randomized studies were identified.

Table 1: Selection Criteria

Criteria	Description
Population	Adults with ADHD
Intervention	Extended-release methylphenidate with an osmotic-controlled release oral [delivery] system
Comparator	Extended-release, controlled-release, or long-acting oral methylphenidate with a different delivery mechanism
Outcomes	Clinical effectiveness (e.g., behavioural, functional, developmental, or cognitive outcomes; health-related quality of life; changes in severity of ADHD symptoms, time to onset of effectiveness, duration of effectiveness; safety [e.g., adverse events])
Study designs	Health technology assessments, systematic reviews, randomized controlled trials, non-randomized studies

ADHD = attention-deficit/hyperactivity disorder.

Additional references of potential interest that did not meet the inclusion criteria are provided in [Appendix 1](#).

Overall Summary of Findings

One randomized controlled trial¹ was identified about the clinical effectiveness of extended-release methylphenidate with an OROS for the treatment of attention-deficit/hyperactivity disorder in adults. The authors of this double-blind cross-over study found that satisfaction with efficacy and side effects was greater with the use of extended-release methylphenidate with an OROS (Concerta) compared to the same dose of generic non-OROS extended-release Novo-methylphenidate ER-C.¹ All study participants preferred to continue treatment with Concerta instead of the generic.¹

References

Health Technology Assessments

No literature identified.

Systematic Reviews

No literature identified.

Randomized Controlled Trials

1. Fallu, A., Dabouz, F., Furtado, M., Anand, L., Katzman, M. A. A randomized, double-blind, cross-over, phase IV trial of oros-methylphenidate (CONCERTA(R)) and generic novo-methylphenidate ER-C (NOVO-generic). *Ther Adv Psychopharmacol.* Aug 2016; 6(4): 237-51. [PubMed](#)

Non-Randomized Studies

No literature identified.

Appendix 1: References of Potential Interest

Previous CADTH Reports

Duration of dosage effect for methylphenidate SR and dextroamphetamine SR for patients with attention deficit hyperactivity disorder. (*CADTH rapid response report: summary of abstracts*). Ottawa (ON): CADTH; 2015: https://www.cadth.ca/sites/default/files/pdf/htis/sep-2015/RB0904_ADHD_Long-Acting_Agents_Final.pdf. Accessed 2022 Aug 17.

Systematic Reviews

Mixed Population – People of Any Age

Coghill, D., Banaschewski, T., Zuddas, A., Pelaz, A., Gagliano, A., Doepfner, M. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies. *BMC Psychiatry*. Sep 27 2013; 13(): 237. [PubMed](#)

Randomized Controlled Trials

Alternative Population - Pediatric

Lee, S. H., Seo, W. S., Sung, H. M., Choi, T. Y., Kim, S. Y., Choi, S. J., Koo, B. H., Lee, J. H. Effect of methylphenidate on sleep parameters in children with ADHD. *Psychiatry Investig*. Dec 2012; 9(4): 384-90. [PubMed](#)

Non-Randomized Studies

Mixed Population – People Aged 6 to 65 Years

Fife, D., Cepeda, M. S., Baseman, A., Richards, H., Hu, P., Starr, H. L., Sena, A. G. Medication changes after switching from CONCERTA R brand methylphenidate HCl to a generic long-acting formulation: A retrospective database study. *PLoS ONE [Electronic Resource]*. 2018; 13(2): e0193453. [PubMed](#)

Unclear Population – Adults Not Specified

Park-Wyllie, L., van Stralen, J., Castillon, G., Sherman, S. E., Almagor, D. Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases. *Clin Ther*. Oct 2017; 39(10): 2006-2023. [PubMed](#)

Park-Wyllie, L., Van Stralen, J., Almagor, D., Dobson-Belaire, W., Charland, K., Smith, A., Le Lorier, J. Medication Persistence, Duration of Treatment, and Treatment-switching Patterns Among Canadian Patients Taking Once-daily Extended-release Methylphenidate Medications for Attention-Deficit/Hyperactivity Disorder: A Population-based Retrospective Cohort Study. *Clin Ther*. Aug 2016; 38(8): 1789-802. [PubMed](#)

Alternative Population - Pediatric

Roh H, Kim B. A Brief Replication Study Comparing Stimulants and Non-Stimulants for Attention-Deficit/Hyperactivity Disorder Treatment with a Focus on the Compliance, Efficacy, and Satisfaction. *Soa Chongsomyon Chongsin Uihak*. 2021;32(1):10-16. [PubMed](#)

Cikili Uytun, M., Cetin, F. H., Babadagi, Z. Parent-reported social problems and clinician-evaluated adverse effects may be differentially affected by differing extended release methylphenidate formulations: a prospective, naturalistic study from Turkey. *Psychiatry Clin Psychopharm*. 02 Oct 2019; 29(4): 722-729.

van Stralen, J. P. The clinical impact of switching attention deficit hyperactivity disorder patients from OROS(R)-MPH to Novo-MPH ER-C(R): A paediatric practice review. *Paediatr Child Health*. Feb 2013; 18(2): 70-3. [PubMed](#)

Review Articles

Mardomingo-Sanz, M. J. Clinical use of 30: 70 controlled-release methylphenidate in the treatment of attention deficit hyperactivity disorder. *Rev Neurol*. 2012; 55(6): 359-369. [PubMed](#)

Additional References

Case Series

Lally, M. D., Kral, M. C., Boan, A. D. Not All Generic Concerta Is Created Equal: Comparison of OROS Versus Non-OROS for the Treatment of ADHD. *Clin Pediatr (Phila)*. Nov 2016; 55(13): 1197-1201. [PubMed](#)

Drug Class Review

Drugs used in the management of attention-deficit/hyperactivity disorder in adults. Final consolidated report. Toronto (ON): Ontario Drug Policy Research Network (ODPRN); 2015: https://odprn.ca/wp-content/uploads/2015/12/ADHD-Final-Consolidated-Report_December-21-15.pdf. Accessed 2022 Aug 17. See "Methylphenidate, osmotic-release oral system" row in Exhibits 5 and 6 (page 25-26); Safety (page 30)